Concepts (150)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prefrontal Cortex | 13 | 2019 | 22 | 2.750 |
Why?
|
| Cocaine | 13 | 2015 | 13 | 2.630 |
Why?
|
| Pyramidal Cells | 11 | 2019 | 11 | 2.410 |
Why?
|
| Calcium Channels, L-Type | 6 | 2017 | 20 | 1.950 |
Why?
|
| Neurons | 10 | 2017 | 42 | 1.860 |
Why?
|
| Nucleus Accumbens | 8 | 2011 | 8 | 1.790 |
Why?
|
| HIV-1 | 7 | 2019 | 40 | 1.570 |
Why?
|
| Action Potentials | 9 | 2019 | 33 | 1.340 |
Why?
|
| Animals | 24 | 2019 | 735 | 1.220 |
Why?
|
| Aging | 2 | 2019 | 75 | 1.110 |
Why?
|
| Rats | 20 | 2019 | 155 | 1.100 |
Why?
|
| tat Gene Products, Human Immunodeficiency Virus | 4 | 2015 | 4 | 1.070 |
Why?
|
| Dopamine Uptake Inhibitors | 6 | 2011 | 6 | 1.020 |
Why?
|
| Male | 21 | 2019 | 1041 | 1.020 |
Why?
|
| Calcium | 6 | 2017 | 189 | 0.990 |
Why?
|
| HIV Infections | 3 | 2019 | 72 | 0.780 |
Why?
|
| Rats, Sprague-Dawley | 16 | 2015 | 94 | 0.770 |
Why?
|
| AIDS Dementia Complex | 3 | 2017 | 17 | 0.700 |
Why?
|
| Potassium Channels, Voltage-Gated | 3 | 2019 | 4 | 0.690 |
Why?
|
| Potassium Channels, Inwardly Rectifying | 2 | 2019 | 2 | 0.670 |
Why?
|
| Neuronal Plasticity | 4 | 2009 | 8 | 0.660 |
Why?
|
| Substance Withdrawal Syndrome | 3 | 2010 | 7 | 0.590 |
Why?
|
| Membrane Potentials | 8 | 2016 | 88 | 0.540 |
Why?
|
| Cerebral Cortex | 2 | 2014 | 17 | 0.520 |
Why?
|
| Sodium Channels | 3 | 2006 | 7 | 0.520 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2016 | 2 | 0.500 |
Why?
|
| Receptors, Dopamine D2 | 2 | 2006 | 5 | 0.480 |
Why?
|
| Potassium Channels | 2 | 2006 | 14 | 0.470 |
Why?
|
| Substance-Related Disorders | 3 | 2017 | 20 | 0.470 |
Why?
|
| Patch-Clamp Techniques | 9 | 2016 | 43 | 0.460 |
Why?
|
| Calcium Channels | 4 | 2011 | 72 | 0.430 |
Why?
|
| Homeostasis | 2 | 2011 | 15 | 0.420 |
Why?
|
| Central Nervous System Stimulants | 3 | 2017 | 14 | 0.410 |
Why?
|
| Signal Transduction | 6 | 2017 | 72 | 0.410 |
Why?
|
| In Vitro Techniques | 7 | 2011 | 67 | 0.370 |
Why?
|
| Excitatory Postsynaptic Potentials | 3 | 2011 | 3 | 0.360 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 6 | 2011 | 15 | 0.340 |
Why?
|
| Calcineurin | 2 | 2011 | 3 | 0.320 |
Why?
|
| Receptors, Dopamine D1 | 3 | 2011 | 3 | 0.290 |
Why?
|
| Enzyme Inhibitors | 6 | 2011 | 26 | 0.260 |
Why?
|
| Ion Channels | 1 | 2007 | 52 | 0.260 |
Why?
|
| Inhibitory Postsynaptic Potentials | 1 | 2006 | 1 | 0.260 |
Why?
|
| Cyclic AMP | 3 | 2005 | 10 | 0.250 |
Why?
|
| Disease Models, Animal | 3 | 2017 | 98 | 0.240 |
Why?
|
| Phosphoproteins | 1 | 2005 | 3 | 0.230 |
Why?
|
| Nerve Tissue Proteins | 1 | 2005 | 27 | 0.230 |
Why?
|
| Muscarine | 1 | 2004 | 2 | 0.230 |
Why?
|
| beta Catenin | 2 | 2017 | 7 | 0.220 |
Why?
|
| Methamphetamine | 2 | 2017 | 5 | 0.220 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2011 | 60 | 0.220 |
Why?
|
| Dopamine Agonists | 4 | 2011 | 5 | 0.220 |
Why?
|
| Calcium Signaling | 1 | 2004 | 61 | 0.220 |
Why?
|
| Humans | 5 | 2017 | 1892 | 0.210 |
Why?
|
| Time Factors | 5 | 2011 | 143 | 0.210 |
Why?
|
| Amphetamine | 1 | 2002 | 1 | 0.190 |
Why?
|
| Ventral Tegmental Area | 1 | 2002 | 1 | 0.190 |
Why?
|
| Electric Stimulation | 4 | 2011 | 23 | 0.180 |
Why?
|
| Rats, Transgenic | 2 | 2017 | 2 | 0.170 |
Why?
|
| Dopamine | 3 | 2007 | 13 | 0.170 |
Why?
|
| Analysis of Variance | 2 | 2011 | 22 | 0.160 |
Why?
|
| Drug Interactions | 3 | 2011 | 7 | 0.160 |
Why?
|
| Dopamine Antagonists | 3 | 2011 | 3 | 0.160 |
Why?
|
| Astrocytes | 2 | 2017 | 5 | 0.160 |
Why?
|
| RNA, Messenger | 1 | 2019 | 38 | 0.150 |
Why?
|
| Drug Administration Schedule | 3 | 2011 | 7 | 0.150 |
Why?
|
| Self Administration | 2 | 2015 | 4 | 0.150 |
Why?
|
| Salicylamides | 2 | 2011 | 2 | 0.140 |
Why?
|
| Quinpirole | 2 | 2011 | 2 | 0.140 |
Why?
|
| Gene Expression | 1 | 2017 | 27 | 0.140 |
Why?
|
| Gene Expression Regulation | 3 | 2017 | 26 | 0.130 |
Why?
|
| Mice, Transgenic | 1 | 2016 | 24 | 0.120 |
Why?
|
| Cortical Excitability | 1 | 2015 | 1 | 0.120 |
Why?
|
| Drug-Seeking Behavior | 1 | 2015 | 2 | 0.110 |
Why?
|
| Cues | 1 | 2015 | 6 | 0.110 |
Why?
|
| Organ Culture Techniques | 1 | 2014 | 2 | 0.110 |
Why?
|
| Potassium Channel Blockers | 3 | 2009 | 3 | 0.100 |
Why?
|
| Motor Cortex | 2 | 2009 | 3 | 0.090 |
Why?
|
| Reward | 2 | 2010 | 3 | 0.090 |
Why?
|
| Nitric Oxide Synthase Type I | 1 | 2010 | 5 | 0.090 |
Why?
|
| Cross-Linking Reagents | 1 | 2009 | 2 | 0.080 |
Why?
|
| Protein Transport | 1 | 2009 | 4 | 0.080 |
Why?
|
| Sodium Channel Blockers | 2 | 2006 | 2 | 0.080 |
Why?
|
| Motor Activity | 1 | 2009 | 20 | 0.080 |
Why?
|
| Synapses | 1 | 2009 | 3 | 0.080 |
Why?
|
| Phosphorylation | 2 | 2005 | 23 | 0.070 |
Why?
|
| Calcium Channel Blockers | 2 | 2005 | 13 | 0.070 |
Why?
|
| Receptors, Dopamine | 1 | 2007 | 3 | 0.070 |
Why?
|
| Adaptation, Physiological | 1 | 2007 | 16 | 0.070 |
Why?
|
| Synaptic Transmission | 1 | 2006 | 4 | 0.060 |
Why?
|
| Type C Phospholipases | 1 | 2006 | 2 | 0.060 |
Why?
|
| Ion Channel Gating | 1 | 2006 | 52 | 0.060 |
Why?
|
| Dopamine and cAMP-Regulated Phosphoprotein 32 | 1 | 2005 | 1 | 0.060 |
Why?
|
| Protein Phosphatase 1 | 1 | 2005 | 1 | 0.060 |
Why?
|
| Adenylyl Cyclases | 1 | 2005 | 8 | 0.060 |
Why?
|
| Blotting, Western | 1 | 2005 | 19 | 0.060 |
Why?
|
| Atropine | 1 | 2004 | 1 | 0.060 |
Why?
|
| Muscarinic Antagonists | 1 | 2004 | 1 | 0.060 |
Why?
|
| Thionucleotides | 1 | 2004 | 2 | 0.060 |
Why?
|
| Pertussis Toxin | 1 | 2004 | 2 | 0.060 |
Why?
|
| Parasympathomimetics | 1 | 2004 | 4 | 0.060 |
Why?
|
| Egtazic Acid | 1 | 2004 | 9 | 0.060 |
Why?
|
| Chelating Agents | 1 | 2004 | 6 | 0.060 |
Why?
|
| Models, Neurological | 1 | 2004 | 4 | 0.060 |
Why?
|
| Microinjections | 1 | 2002 | 1 | 0.050 |
Why?
|
| Genes, Immediate-Early | 1 | 2002 | 1 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2017 | 2 | 0.030 |
Why?
|
| Cellular Senescence | 1 | 2017 | 3 | 0.030 |
Why?
|
| Primary Cell Culture | 1 | 2017 | 5 | 0.030 |
Why?
|
| Animals, Genetically Modified | 1 | 2017 | 3 | 0.030 |
Why?
|
| Microfilament Proteins | 1 | 2017 | 5 | 0.030 |
Why?
|
| Excitatory Amino Acid Antagonists | 2 | 2009 | 5 | 0.030 |
Why?
|
| Calcium-Binding Proteins | 1 | 2017 | 12 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2017 | 21 | 0.030 |
Why?
|
| Mice | 1 | 2017 | 209 | 0.030 |
Why?
|
| Conditioning, Operant | 1 | 2015 | 1 | 0.030 |
Why?
|
| Rats, Inbred F344 | 1 | 2015 | 7 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2012 | 18 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 12 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2011 | 19 | 0.020 |
Why?
|
| Cell Line | 1 | 2011 | 43 | 0.020 |
Why?
|
| Comorbidity | 1 | 2011 | 27 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2011 | 10 | 0.020 |
Why?
|
| Indazoles | 1 | 2010 | 1 | 0.020 |
Why?
|
| Behavior, Animal | 1 | 2010 | 8 | 0.020 |
Why?
|
| Cocaine-Related Disorders | 1 | 2010 | 4 | 0.020 |
Why?
|
| Disks Large Homolog 4 Protein | 1 | 2009 | 1 | 0.020 |
Why?
|
| Apamin | 1 | 2009 | 1 | 0.020 |
Why?
|
| Macrolides | 1 | 2009 | 1 | 0.020 |
Why?
|
| Small-Conductance Calcium-Activated Potassium Channels | 1 | 2009 | 1 | 0.020 |
Why?
|
| Tissue Culture Techniques | 1 | 2009 | 2 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2009 | 5 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2009 | 2 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2009 | 3 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2009 | 5 | 0.020 |
Why?
|
| RNA Interference | 1 | 2009 | 4 | 0.020 |
Why?
|
| Biophysics | 1 | 2009 | 19 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2009 | 12 | 0.020 |
Why?
|
| Peptides | 1 | 2009 | 16 | 0.020 |
Why?
|
| Kynurenic Acid | 1 | 2005 | 1 | 0.010 |
Why?
|
| GABA Antagonists | 1 | 2005 | 1 | 0.010 |
Why?
|
| Cadmium Chloride | 1 | 2005 | 1 | 0.010 |
Why?
|
| Tetraethylammonium | 1 | 2005 | 1 | 0.010 |
Why?
|
| Tetrodotoxin | 1 | 2005 | 2 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2005 | 3 | 0.010 |
Why?
|
| Cesium | 1 | 2005 | 5 | 0.010 |
Why?
|
| Chlorides | 1 | 2005 | 8 | 0.010 |
Why?
|
| Nifedipine | 1 | 2005 | 2 | 0.010 |
Why?
|
| Evoked Potentials | 1 | 2004 | 2 | 0.010 |
Why?
|
| Barium | 1 | 2004 | 7 | 0.010 |
Why?
|
| Cell Separation | 1 | 2004 | 3 | 0.010 |
Why?
|